AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

LISTING OF CLAIMS

1-14. Canceled

15. (Previously presented) A method of inhibiting the activity of a chemokine, said method comprising contacting a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19, CCL5, CXCL9 and CXCL10 with an agent comprising a polypeptide selected from the group consisting of SEQ ID NO: 3 and a chemokine-binding domain of SEQ ID NO: 3, wherein the activity of said chemokine is inhibited.

16. (Canceled)

17. (Original) The method of Claim 15, wherein said polypeptide is fused to an Fc region of an immunoglobulin.

18. (Previously presented) The method of Claim 15, wherein said polypeptide comprises a Thanatos (death) associated protein (THAP) dimerization domain.

19. (Previously presented) The method of Claim 18, wherein said Thanatos (death) associated protein (THAP) dimerization domain interacts with one or more THAP dimerization domains to form a THAP oligomer.

20. (Original) The method of Claim 15, wherein said polypeptide is a recombinant polypeptide.

21. (Canceled)

22. (Previously presented) The method of Claim 15, wherein said polypeptide binds to a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19 and CXCL9.

23. (Canceled)

24. (Previously presented) The method of Claim 15, wherein said polypeptide is SEQ ID NO: 3.

25. (Canceled)

26. (Previously presented) The method of Claim 15, wherein said polypeptide is a chemokine-binding domain of SEQ ID NO: 3.

27. (Previously presented) The method of Claim 26, wherein said chemokine-binding domain of SEQ ID NO: 3 comprises the amino acid sequence 143-213 of SEQ ID NO: 3.

28-91. (Canceled)

92. (Previously presented) The method of Claim 15, wherein said polypeptide comprises an isolated polypeptide.

93. (Canceled)

94. (Previously presented) The method of Claim 92, wherein said polypeptide binds to a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19 and CXCL9.

95. (Previously presented) The method of Claim 92, wherein said polypeptide is SEQ ID NO: 3.

96. (Canceled)

97. (Previously presented) The method of Claim 92, wherein said polypeptide is a chemokine-binding domain of SEQ ID NO: 3.

98. (Canceled)

99. (Previously presented) The method of Claim 15, wherein said polypeptide binds to CCL5.

100. (Previously presented) The method of Claim 92, wherein said polypeptide binds to CCL5.

101. (Previously presented) A method of binding a chemokine, said method comprising contacting a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19, CCL5, CXCL9 and CXCL10 with an agent comprising a polypeptide selected from the group consisting of SEQ ID NO: 3 and a chemokine-binding domain of SEQ ID NO: 3, wherein the chemokine is bound.

102. (Previously presented) The method of Claim 101, wherein said polypeptide is fused to an Fc region of an immunoglobulin.

103. (Previously presented) The method of Claim 101, wherein said polypeptide comprises a Thanatos (death) associated protein (THAP) dimerization domain.

104. (Previously presented) The method of Claim 103, wherein said THAP dimerization domain interacts with one or more Thanatos (death) associated protein (THAP) dimerization domains to form a THAP oligomer.

105. (Previously presented) The method of Claim 101, wherein said polypeptide is a recombinant polypeptide.

106. (Canceled)

107. (Previously presented) The method of Claim 101, wherein said polypeptide binds to a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19 and CXCL9.

108. (Previously presented) The method of Claim 101, wherein said polypeptide is SEQ ID NO: 3.

109. (Canceled)

110. (Previously presented) The method of Claim 101, wherein said polypeptide is a chemokine-binding domain of SEQ ID NO: 3.

111. (Previously presented) The method of Claim 110, wherein said chemokine-binding domain of SEQ ID NO: 3 comprises the amino acid sequence 143-213 of SEQ ID NO: 3.

112. (Canceled)

113. (Previously presented) The method of Claim 101, wherein said polypeptide comprises an isolated polypeptide.

114. (Canceled)

115. (Previously presented) The method of Claim 101, wherein said polypeptide binds to a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19 and CXCL9.

116. (Previously presented) The method of Claim 101, wherein said polypeptide is SEQ ID NO: 3.

117. (Canceled)

118. (Previously presented) The method of Claim 101, wherein said polypeptide is a chemokine-binding domain of SEQ ID NO: 3.

119. (Canceled)

120. (Previously presented) The method of Claim 101, wherein said polypeptide binds CCL5.

121. (Previously presented) The method of Claim 113, wherein said polypeptide binds CCL5.

122. (New) A method of inhibiting the activity of a chemokine, said method comprising contacting a chemokine with an agent comprising a polypeptide selected from the group consisting of SEQ ID NO: 3, a polypeptide having at least 95% sequence identity to SEQ ID NO: 3, a chemokine-binding domain of SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3, wherein the activity of said chemokine is inhibited.

123. (New) The method of claim 122, wherein said polypeptide is selected from the group consisting of SEQ ID NO: 3 and a chemokine-binding domain of SEQ ID NO: 3.

124. (New) The method of claim 122, wherein polypeptide is selected from the group consisting of a polypeptide having at least 95% sequence identity to SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.

125. (New) The method of claim 122, wherein said polypeptide is SEQ ID NO: 3.

126. (New) The method of claim 122, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 3.

127. (New) The method of claim 122, wherein said polypeptide is a chemokine-binding domain of SEQ ID NO: 3.

128. (New) The method of claim 127, wherein said chemokine-binding domain of SEQ ID NO: 3 comprises the amino acid sequence 143-213 of SEQ ID NO: 3.

129. (New) The method of claim 122, wherein said polypeptide has at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.

130. (New) A method of inhibiting the activity of a chemokine, said method comprising contacting a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19, CCL5, CXCL9 and CXCL10 with an agent comprising a polypeptide selected from the group consisting of SEQ ID NO: 3, a polypeptide having at least

95% sequence identity to SEQ ID NO: 3, a chemokine-binding domain of SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3, wherein the activity of said chemokine is inhibited.

131. (New) The method of claim 130, wherein said chemokine is selected from the group consisting of SLC, CCL19 and CCL5.

132. (New) The method of claim 130, wherein said chemokine is selected from the group consisting of CXCL9 and CXCL10.

133. (New) The method of claim 130, wherein said chemokine is SLC.

134. (New) The method of claim 130, wherein said chemokine is CC19.

135. (New) The method of claim 130, wherein said chemokine is CC5.

136. (New) The method of claim 130, wherein said chemokine is CXCL9.

137. (New) The method of claim 130, wherein said chemokine is CXCL10.

138. (New) The method of claim 130, wherein said polypeptide selected from the group consisting of a polypeptide having at least 95% sequence identity to SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3, wherein the activity of said chemokine is inhibited.

139. (New) The method of claim 130, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 3.

140. (New) The method of claim 130, wherein said polypeptide has at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.

141. (New) The method of claim 140, wherein said chemokine-binding domain of SEQ ID NO: 3 comprises the amino acid sequence 143-213 of SEQ ID NO: 3.

142. (New) A method of binding a chemokine, said method comprising contacting a chemokine with an agent comprising a polypeptide selected from the group consisting of SEQ ID NO: 3, a polypeptide having at least 95% sequence identity to SEQ ID NO: 3, a chemokine-binding domain of SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3, wherein said chemokine is bound.

143. (New) The method of claim 142, wherein said polypeptide is selected from the group consisting of SEQ ID NO: 3 and a chemokine-binding domain of SEQ ID NO: 3.

144. (New) The method of claim 142, wherein polypeptide is selected from the group consisting of a polypeptide having at least 95% sequence identity to SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.

145. (New) The method of claim 142, wherein said polypeptide is SEQ ID NO: 3.

146. (New) The method of claim 142, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 3.

147. (New) The method of claim 142, wherein said polypeptide is a chemokine-binding domain of SEQ ID NO: 3.

148. (New) The method of claim 147, wherein said chemokine-binding domain of SEQ ID NO: 3 comprises the amino acid sequence 143-213 of SEQ ID NO: 3.

149. (New) The method of claim 142, wherein said polypeptide has at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.

150. (New) A method of binding a chemokine, said method comprising contacting a chemokine selected from the group consisting of Secondary Lymphoid-tissue Chemokine (SLC), CCL19, CCL5, CXCL9 and CXCL10 with an agent comprising a polypeptide selected from the group consisting of SEQ ID NO: 3, a polypeptide having at least 95% sequence identity to SEQ ID NO: 3, a chemokine-binding domain of SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3, wherein said chemokine is bound.

151. (New) The method of claim 150, wherein said chemokine is selected from the group consisting of SLC, CCL19 and CCL5.

152. (New) The method of claim 150, wherein said chemokine is selected from the group consisting of CXCL9 and CXCL10.

153. (New) The method of claim 150, wherein said chemokine is SLC.

154. (New) The method of claim 150, wherein said chemokine is CC19.

155. (New) The method of claim 150, wherein said chemokine is CC5.

156. (New) The method of claim 150, wherein said chemokine is CXCL9.

157. (New) The method of claim 150, wherein said chemokine is CXCL10.

158. (New) The method of claim 150, wherein said polypeptide selected from the group consisting of a polypeptide having at least 95% sequence identity to SEQ ID NO: 3 and a polypeptide having at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3, wherein the activity of said chemokine is inhibited.

159. (New) The method of claim 150, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 3.

160. (New) The method of claim 150, wherein said polypeptide has at least 95% sequence identity to a chemokine-binding domain of SEQ ID NO: 3.

161. (New) The method of claim 160, wherein said chemokine-binding domain of SEQ ID NO: 3 comprises the amino acid sequence 143-213 of SEQ ID NO: 3.